ATE248160T1 - Pyridin acetylcholin-rezeptor-modulatoren - Google Patents
Pyridin acetylcholin-rezeptor-modulatorenInfo
- Publication number
- ATE248160T1 ATE248160T1 AT95937421T AT95937421T ATE248160T1 AT E248160 T1 ATE248160 T1 AT E248160T1 AT 95937421 T AT95937421 T AT 95937421T AT 95937421 T AT95937421 T AT 95937421T AT E248160 T1 ATE248160 T1 AT E248160T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- disease
- compounds
- pyridine
- acetylcholine receptor
- Prior art date
Links
- 108010009685 Cholinergic Receptors Proteins 0.000 title abstract 4
- 102000034337 acetylcholine receptors Human genes 0.000 title abstract 4
- -1 PYRIDINE ACETYLCHOLINE Chemical compound 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 5
- 206010012289 Dementia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000027534 Emotional disease Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000002567 autonomic effect Effects 0.000 abstract 1
- 210000002318 cardia Anatomy 0.000 abstract 1
- 230000004706 cardiovascular dysfunction Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 230000007661 gastrointestinal function Effects 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000007659 motor function Effects 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 208000028591 pheochromocytoma Diseases 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/337,640 US5594011A (en) | 1994-11-10 | 1994-11-10 | Modulators of acetylcholine receptors |
| US08/485,398 US5703100A (en) | 1994-11-10 | 1995-06-07 | Modulators of acetylcholine receptors |
| PCT/US1995/013068 WO1996015123A1 (en) | 1994-11-10 | 1995-10-16 | Pyridine modulators of acetylcholine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE248160T1 true ATE248160T1 (de) | 2003-09-15 |
Family
ID=26990807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95937421T ATE248160T1 (de) | 1994-11-10 | 1995-10-16 | Pyridin acetylcholin-rezeptor-modulatoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5703100A (de) |
| EP (1) | EP0739342B1 (de) |
| JP (1) | JP3802928B2 (de) |
| AT (1) | ATE248160T1 (de) |
| AU (1) | AU693285B2 (de) |
| CA (1) | CA2180843C (de) |
| DE (1) | DE69531603T2 (de) |
| ES (1) | ES2204968T3 (de) |
| WO (1) | WO1996015123A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US5629325A (en) * | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| EP1083913A4 (de) * | 1998-06-05 | 2004-03-17 | Regent Court Technologies | Monoaminoxidase (mao) inhibitoren und ihre verwendung . |
| US6506378B1 (en) | 1998-12-16 | 2003-01-14 | Arch Development Corporation | Vesicular monoamine transporter gene therapy in Parkinson's disease |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| US7414055B2 (en) | 2003-04-24 | 2008-08-19 | Merck & Co., Inc. | Inhibitors of Akt activity |
| AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| RU2259364C1 (ru) * | 2004-04-01 | 2005-08-27 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, включающие фрагмент пиперидин-2-ила-, фокусированные библиотеки и фармацевтические композиции |
| WO2004103991A1 (en) * | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | 2-substituted piperidines, focused library and a pharmaceutical compound |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| DE60329721D1 (de) * | 2003-11-17 | 2009-11-26 | Univ North Carolina State | Regiospezifische synthese von nikotinderivaten |
| JP4639327B2 (ja) * | 2004-07-16 | 2011-02-23 | 国立大学法人高知大学 | 光学活性アミノピリジル基含有ピロリジン誘導体及びそれを用いた不斉合成方法 |
| JP2009531442A (ja) * | 2006-03-29 | 2009-09-03 | ノース・キャロライナ・ステイト・ユニヴァーシティ | ６−ハロおよび６−アルコキシニコチン誘導体の合成および位置選択的置換 |
| EP1977746B8 (de) | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| CN114437025B (zh) * | 2020-11-05 | 2023-08-25 | 上海零诺生物科技有限公司 | 消旋6-甲基烟碱及其制备方法、以及应用 |
| WO2026013602A1 (en) | 2024-07-10 | 2026-01-15 | Rai Strategic Holdings, Inc. | Oral products |
| WO2026047620A1 (en) | 2024-08-30 | 2026-03-05 | Rai Strategic Holdings, Inc. | Aerosolizable composition including a substituted 3-(1-methylpyrrolidin-2-yl)pyridine compound |
| WO2026083320A1 (en) | 2024-10-18 | 2026-04-23 | Rai Strategic Holdings, Inc. | Aerosol generating material comprising a substituted 3-(1-methylpyrrolidin-2-yl)pyridine |
| WO2026083326A2 (en) | 2024-10-18 | 2026-04-23 | Rai Strategic Holdings, Inc. | Aerosol generating material comprising a substituted 3-(1-methylpyrrolidin-2-yl)pyridine compound |
| WO2026083322A1 (en) | 2024-10-18 | 2026-04-23 | Rai Strategic Holdings, Inc. | End plug comprising a substituted 3-(1-methylpyrrolidin-2-yl)pyridine |
| WO2026083323A1 (en) | 2024-10-18 | 2026-04-23 | Rai Strategic Holdings, Inc. | Aerosol-modifying additive comprising a substituted 3-(1methylpyrrolidin-2-yl)pyridine |
| WO2026083313A2 (en) | 2024-10-18 | 2026-04-23 | Rai Strategic Holdings, Inc. | Aerosol generating gel material comprising a substituted 3-(1-methylpyrrolidin-2-yl)pyridine |
| WO2026083317A1 (en) | 2024-10-18 | 2026-04-23 | Rai Strategic Holdings, Inc. | Aerosol generating material in discrete portions comprising a substituted 3-(1-methylpyrrolidin-2-yl)pyridine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3247213A (en) * | 1961-04-12 | 1966-04-19 | Shell Oil Co | Heterocyclic nitrogen compounds |
| NL7008619A (de) * | 1969-06-25 | 1970-12-29 | Merck & Co Inc | |
| US4155909A (en) * | 1977-06-13 | 1979-05-22 | Philip Morris Incorporated | 2-Alkyl nicotinoids and processes for their production |
| US4321387A (en) * | 1980-03-21 | 1982-03-23 | Philip Morris, Incorporated | Process for the preparation of optically active nicotine analogs |
| US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
| JPH03135978A (ja) * | 1989-08-08 | 1991-06-10 | Merck Sharp & Dohme Ltd | 置換ピリジン、その製法、処方並びに痴呆症における使用法 |
| US5418229A (en) * | 1990-01-06 | 1995-05-23 | Alker; David | Muscarinic receptor antagonists |
| DE4038335A1 (de) * | 1990-12-01 | 1992-06-04 | Boehringer Mannheim Gmbh | Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| AU652434B2 (en) * | 1991-03-01 | 1994-08-25 | University Of Florida Research Foundation, Inc. | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| JP3153551B2 (ja) * | 1991-05-29 | 2001-04-09 | アボツト・ラボラトリーズ | 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物 |
| CA2080536A1 (en) * | 1991-10-17 | 1993-04-18 | John S. Ward | Nicotinic activity of a series of arecolones and isoarecolones |
| US5242935A (en) * | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5227391A (en) * | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5187169A (en) * | 1992-04-10 | 1993-02-16 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5232933A (en) * | 1992-05-21 | 1993-08-03 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5248690A (en) * | 1992-07-07 | 1993-09-28 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
| EP0659078B1 (de) * | 1992-08-31 | 2003-01-15 | University Of Florida Research Foundation, Inc. | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems |
-
1995
- 1995-06-07 US US08/485,398 patent/US5703100A/en not_active Expired - Lifetime
- 1995-10-16 WO PCT/US1995/013068 patent/WO1996015123A1/en not_active Ceased
- 1995-10-16 ES ES95937421T patent/ES2204968T3/es not_active Expired - Lifetime
- 1995-10-16 EP EP95937421A patent/EP0739342B1/de not_active Expired - Lifetime
- 1995-10-16 JP JP51556696A patent/JP3802928B2/ja not_active Expired - Fee Related
- 1995-10-16 CA CA002180843A patent/CA2180843C/en not_active Expired - Fee Related
- 1995-10-16 DE DE69531603T patent/DE69531603T2/de not_active Expired - Lifetime
- 1995-10-16 AU AU39544/95A patent/AU693285B2/en not_active Ceased
- 1995-10-16 AT AT95937421T patent/ATE248160T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU693285B2 (en) | 1998-06-25 |
| AU3954495A (en) | 1996-06-06 |
| CA2180843A1 (en) | 1996-05-23 |
| CA2180843C (en) | 2003-07-15 |
| JP3802928B2 (ja) | 2006-08-02 |
| ES2204968T3 (es) | 2004-05-01 |
| DE69531603T2 (de) | 2004-06-24 |
| WO1996015123A1 (en) | 1996-05-23 |
| US5703100A (en) | 1997-12-30 |
| DE69531603D1 (de) | 2003-10-02 |
| EP0739342A1 (de) | 1996-10-30 |
| JPH09508648A (ja) | 1997-09-02 |
| EP0739342B1 (de) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69531603D1 (de) | Pyridin acetylcholin-rezeptor-modulatoren | |
| DE69632916D1 (de) | Substituierte Pyridinderivate, deren Herstellung und deren Verwendung als Modulatoren von Acetylcholin-Rezeptoren | |
| DE69628333D1 (de) | Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren | |
| MX9706969A (es) | 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos. | |
| PL316143A1 (en) | Precursors of morpholinic tachykinin receptor antagonists | |
| EP0835869A3 (de) | Serotonin-5-HT1F-Rezeptor Agoniste | |
| NO963785L (no) | Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser | |
| MY138267A (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| WO2001068112A3 (en) | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility | |
| AU1856397A (en) | Heterocyclic derivatives as antidiabetic and antiobesity agents | |
| MY115164A (en) | Morpholine and thiomorpholine tachykinin receptor antagonists | |
| WO2002059112A3 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| EP0904079A4 (de) | ||
| DK0749428T3 (da) | Isooxazolinforbindelser som inhibitorer af TNF-frigivelse | |
| TR199801255T2 (xx) | Vitronektin resept�r antagonistleri. | |
| NO940927L (no) | Kondenserte tricykliske nitrogenholdige heterocykler som substans-P-reseptor-antagonister | |
| IL125590A0 (en) | Peptide immunogens | |
| DE69827684D1 (de) | Neue Lactobazillus-Stämme zur Behandlung von Störungen des Gastrointestinaltraktes | |
| DK1267869T3 (da) | Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed | |
| GR3018442T3 (en) | Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders. | |
| ZA983325B (en) | NK-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome. | |
| BR9510499A (pt) | Antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados po il-5 | |
| DE60312474D1 (de) | 5-ht3-rezeptorantagonisten und verwendungsverfahren | |
| SG48816A1 (en) | Gonococcal anti-idiotypic antibodies and methods and compositions using them | |
| DK1105390T3 (da) | Imidazo(1,2a)pyridinderivater til behandling af gastrointestinale sygdomme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |